Gabriela Macedo Fraiz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Gabriela Macedo Fraiz has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Josefina Bressan
Department of Nutrition and Health, Universidade Federal de Viçosa
6 shared publications - Fermin Ignacio Milagro
Center for Nutrition Research, University of Navarra, 31008 Pamplona, Spain
5 shared publications - Frederico Augusto Ribeiro de Barros
Department of Food and Technology Universidade Federal de Viçosa Viçosa Brazil
5 shared publications - Dandara Baia Bonifácio
Department of Nutrition and Health Universidade Federal de Viçosa Viçosa Brazil
4 shared publications - Alessio Giacomini
Department of Agronomy, Food, Natural Resources Animal and Environment (DAFNAE) University of Padova Padova Italy
3 shared publications - Hércia Stampini Duarte Martino
Department of Nutrition and Health Federal University of Viçosa Viçosa Minas Gerais Brazil
3 shared publications
Latest Publications
- Open Access
- 23 March 2026
- Published by Springer Nature in Clinical Oral Investigations
- Vol. 30 (4)
Sex-specific differences in salivary microbiota composition and their associations with metabolic health in adults with excess body weight: a secondary cross-sectional analysis
Objectives: Growing evidence links the oral microbiome to obesity-related outcomes, yet the influence of sex-related biological differences on salivary microbial profiles remains insufficiently explored. This exploratory study aimed to characterize the composition, abundance, and diversity of the salivary microbiota in Brazilian men and women with excess body weight and to examine its associations with cardiometabolic markers. Materials and methods: This cross-sectional secondary analysis of a randomized controlled trial (REBEC: RBR-9832wsx) included 59 adults with excess body weight. Salivary microbiota was profiled through amplification of the 16 S rRNA V4 region, and bioinformatics analyses were performed using the Microbiome Analyst (v2.0). Associations between microbial taxa and clinical variables were assessed using Spearman’s correlation. Results: Men exhibited greater alpha diversity at the family level by higher Shannon ( p = 0.015, r rb = 0.4) and Simpson ( p = 0.003, r rb = 0.5) indices. Sex-specific microbial differences were identified: men showed higher levels of genera Tannerella , Lachnoanaerobaculum , and Actinomyces , as well as the putative species-level taxons Tannerella serpentiformis and Lachnoanaerobaculum umeaense , whereas women demonstrated greater abundance of genera Campylobacter , Granulicatella , Moryella , and Scardovia . Among women, Granulicatella genera was positively associated with triglycerides and the TyG index. Conclusion: Men and women with excess body weight exhibited distinct salivary microbiota profiles, with differences in both diversity and taxonomic composition. Clinical relevance: Sex-specific differences in salivary microbiota composition may be associated with variations in metabolic markers. These findings are exploratory and hypothesis-generating, providing insight into sex-related patterns in the oral microbiome and may help inform future research exploring personalized approaches to cardiometabolic risk assessment.
- 23 March 2026
- Published by Springer Nature in Clinical Oral Investigations
- Vol. 30 (4)
Open AccessSex-specific differences in salivary microbiota composition and their associations with metabolic health in adults with excess body weight: a secondary cross-sectional analysis
Objectives: Growing evidence links the oral microbiome to obesity-related outcomes, yet the influence of sex-related biological differences on salivary microbial profiles remains insufficiently explored. This exploratory study aimed to characterize the composition, abundance, and diversity of the salivary microbiota in Brazilian men and women with excess body weight and to examine its associations with cardiometabolic markers. Materials and methods: This cross-sectional secondary analysis of a randomized controlled trial (REBEC: RBR-9832wsx) included 59 adults with excess body weight. Salivary microbiota was profiled through amplification of the 16 S rRNA V4 region, and bioinformatics analyses were performed using the Microbiome Analyst (v2.0). Associations between microbial taxa and clinical variables were assessed using Spearman’s correlation. Results: Men exhibited greater alpha diversity at the family level by higher Shannon ( p = 0.015, r rb = 0.4) and Simpson ( p = 0.003, r rb = 0.5) indices. Sex-specific microbial differences were identified: men showed higher levels of genera Tannerella , Lachnoanaerobaculum , and Actinomyces , as well as the putative species-level taxons Tannerella serpentiformis and Lachnoanaerobaculum umeaense , whereas women demonstrated greater abundance of genera Campylobacter , Granulicatella , Moryella , and Scardovia . Among women, Granulicatella genera was positively associated with triglycerides and the TyG index. Conclusion: Men and women with excess body weight exhibited distinct salivary microbiota profiles, with differences in both diversity and taxonomic composition. Clinical relevance: Sex-specific differences in salivary microbiota composition may be associated with variations in metabolic markers. These findings are exploratory and hypothesis-generating, providing insight into sex-related patterns in the oral microbiome and may help inform future research exploring personalized approaches to cardiometabolic risk assessment.
- Open Access
- 7 March 2026
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 17 (7) , 3353-3371
Regular black tea kombucha consumption is associated with improved insulin resistance and increased ADIPOQ expression in adults with obesity: a pre–post clinical trial
Kombucha is a fermented beverage obtained by a Symbiotic Culture of Bacteria and Yeast (SCOBY).
- 7 March 2026
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 17 (7) , 3353-3371
Open AccessRegular black tea kombucha consumption is associated with improved insulin resistance and increased ADIPOQ expression in adults with obesity: a pre–post clinical trial
Kombucha is a fermented beverage obtained by a Symbiotic Culture of Bacteria and Yeast (SCOBY).
- Open Access
- 17 June 2025
- Published by MDPI AG in Fermentation
- Vol. 11 (6) , 353
Benefits of Kombucha Consumption: A Systematic Review of Clinical Trials Focused on Microbiota and Metabolic Health
Background: Fermented foods rich in bioactive compounds have been proposed as potential strategy to combat non-communicable diseases. Among them is kombucha, a beverage fermented from sugared Camellia sinensis tea by a symbiotic culture of bacteria and yeasts (SCOBY). Recently, there has been an increased focus on assessing the actual effect of this beverage on human health. In this manner, this systematic review aimed to gather clinical evidence on the impact of kombucha consumption on human health. Methods: The databases Cochrane CENTRAL, MEDLINE/PubMed, and Embase® were searched, and the risk of bias tool used was the Critical Appraisal Tools outlined in the Joanna Briggs Institute. This review followed the PRISMA guidelines and was registered on PROSPERO (CRD42024599464). Results: Eight clinical trials were included (two pre- and post-interventions and six randomized controlled trials) with durations ranging from 10 days to 10 weeks. Two studies reported beneficial effects of kombucha on gastrointestinal symptoms, such as reduced intensity of constipation-related complaints. Two trials observed changes in gut microbiota composition, including increased abundance in Bacteroidota, Akkermansiaceae, Saccharomyces, and Weizmannia coagulans, alongside reductions in Ruminococcus, Dorea, and Rhodotorula. Moreover, five clinical trials evaluated glucose metabolism, evidencing inconsistent results, and other studies identified improvements in salivary microbiota composition and serum metabolomic profile. Conclusion: These findings suggest that kombucha consumption may provide health benefits, particularly in alleviating gastrointestinal symptoms, and demonstrates a modest capacity for modulating gut and salivary microbiota, as well as metabolomic profiles. Although the results are promising, the heterogeneity of the studies and the limited number of available clinical trials highlight the need for further robust research to confirm these effects.
- 17 June 2025
- Published by MDPI AG in Fermentation
- Vol. 11 (6) , 353
Open AccessBenefits of Kombucha Consumption: A Systematic Review of Clinical Trials Focused on Microbiota and Metabolic Health
Background: Fermented foods rich in bioactive compounds have been proposed as potential strategy to combat non-communicable diseases. Among them is kombucha, a beverage fermented from sugared Camellia sinensis tea by a symbiotic culture of bacteria and yeasts (SCOBY). Recently, there has been an increased focus on assessing the actual effect of this beverage on human health. In this manner, this systematic review aimed to gather clinical evidence on the impact of kombucha consumption on human health. Methods: The databases Cochrane CENTRAL, MEDLINE/PubMed, and Embase® were searched, and the risk of bias tool used was the Critical Appraisal Tools outlined in the Joanna Briggs Institute. This review followed the PRISMA guidelines and was registered on PROSPERO (CRD42024599464). Results: Eight clinical trials were included (two pre- and post-interventions and six randomized controlled trials) with durations ranging from 10 days to 10 weeks. Two studies reported beneficial effects of kombucha on gastrointestinal symptoms, such as reduced intensity of constipation-related complaints. Two trials observed changes in gut microbiota composition, including increased abundance in Bacteroidota, Akkermansiaceae, Saccharomyces, and Weizmannia coagulans, alongside reductions in Ruminococcus, Dorea, and Rhodotorula. Moreover, five clinical trials evaluated glucose metabolism, evidencing inconsistent results, and other studies identified improvements in salivary microbiota composition and serum metabolomic profile. Conclusion: These findings suggest that kombucha consumption may provide health benefits, particularly in alleviating gastrointestinal symptoms, and demonstrates a modest capacity for modulating gut and salivary microbiota, as well as metabolomic profiles. Although the results are promising, the heterogeneity of the studies and the limited number of available clinical trials highlight the need for further robust research to confirm these effects.
- Open Access
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Pesquisa Brasileira em Odontopediatria e Clínica Integrada
- Vol. 25, e240112
Consumption of Cariogenic Ultra-processed Foods and Maternal Report of Dental Caries and Dental Pain among Preschool Children
Objective: To assess the association between cariogenic ultra-processed foods (UPF) consumption and maternal reports of dental caries and dental pain among preschool children.
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Pesquisa Brasileira em Odontopediatria e Clínica Integrada
- Vol. 25, e240112
Open AccessConsumption of Cariogenic Ultra-processed Foods and Maternal Report of Dental Caries and Dental Pain among Preschool Children
Objective: To assess the association between cariogenic ultra-processed foods (UPF) consumption and maternal reports of dental caries and dental pain among preschool children.
- Open Access
The Impact of Green Tea Kombucha on the Intestinal Health, Gut Microbiota, and Serum Metabolome of Individuals with Excess Body Weight in a Weight Loss Intervention: A Randomized Controlled Trial
Green tea kombucha (GTK) has emerged as a promising probiotic fermented beverage. Few studies have investigated its effect on human health, mainly focusing on intestinal health, microbiota composition, and metabolomics. The present study is a pioneer in investigating the effect of GTK consumption in individuals with excess body weight. This is a randomized controlled trial, lasting ten weeks, with two groups placed under an energy-restricted diet: control (CG, n = 29), kombucha (KG, n = 30; 200 mL/d). Biological samples and questionnaires were collected before and after the intervention. Microbiota analysis used an amplification of the V4 region of 16S rRNA. Serum untargeted metabolomics used HPLC-TOF mass spectrometry. Intestinal permeability considered the urine excretion of lactulose and mannitol, plasma zonulin, and LPS-binding protein. After the intervention, no differences related to intestinal permeability and microbiota were found between groups, but only the CG had increased fecal pH, lactulose/mannitol ratio, and zonulin. In addition to this, the KG reported lower gastrointestinal symptoms related to motility compared to the CG, and discriminant metabolites (e.g., diethyl malonate) were found strictly in the KG. GTK did not significantly improve gut microbiota and intestinal permeability. However, GTK ameliorated gastrointestinal symptoms and positively influenced the serum metabolome, which may contribute to enhancing the metabolic health of individuals with excess body weight.
Open AccessThe Impact of Green Tea Kombucha on the Intestinal Health, Gut Microbiota, and Serum Metabolome of Individuals with Excess Body Weight in a Weight Loss Intervention: A Randomized Controlled Trial
Green tea kombucha (GTK) has emerged as a promising probiotic fermented beverage. Few studies have investigated its effect on human health, mainly focusing on intestinal health, microbiota composition, and metabolomics. The present study is a pioneer in investigating the effect of GTK consumption in individuals with excess body weight. This is a randomized controlled trial, lasting ten weeks, with two groups placed under an energy-restricted diet: control (CG, n = 29), kombucha (KG, n = 30; 200 mL/d). Biological samples and questionnaires were collected before and after the intervention. Microbiota analysis used an amplification of the V4 region of 16S rRNA. Serum untargeted metabolomics used HPLC-TOF mass spectrometry. Intestinal permeability considered the urine excretion of lactulose and mannitol, plasma zonulin, and LPS-binding protein. After the intervention, no differences related to intestinal permeability and microbiota were found between groups, but only the CG had increased fecal pH, lactulose/mannitol ratio, and zonulin. In addition to this, the KG reported lower gastrointestinal symptoms related to motility compared to the CG, and discriminant metabolites (e.g., diethyl malonate) were found strictly in the KG. GTK did not significantly improve gut microbiota and intestinal permeability. However, GTK ameliorated gastrointestinal symptoms and positively influenced the serum metabolome, which may contribute to enhancing the metabolic health of individuals with excess body weight.
- Open Access
Green Tea Kombucha Impacts Inflammation and Salivary Microbiota in Individuals with Excess Body Weight: A Randomized Controlled Trial
Background: Green tea kombucha (GTK) is a fermented beverage with promising health benefits, but few studies proved its impact on human health. Thus, we aimed to investigate the impact of GTK on weight loss, inflammation, and salivary microbiota in individuals with excess body weight. Methods: This is a randomized controlled clinical trial that lasted 10 weeks with two groups of individuals with excess body weight: control (CG; n = 29; caloric restriction) and kombucha (KG; n = 30; caloric restriction + 200 mL GTK). Body composition, anthropometry, saliva, and blood collection were performed in the beginning and end of the intervention. Plasma interleukins were determined by flow cytometry. Salivary microbiota was analyzed by 16S rRNA sequencing. Results: Both groups decreased weight, BMI, and body fat (p < 0.001) after the intervention, but there were no differences between groups. The KG reduced lipid accumulation product (LAP) (p = 0.029). Both groups decreased IL-1β and IL-8, but IL-6 increased in the CG (p = 0.023) compared to the kombucha group. Alpha and beta diversity of salivary microbiota increased in the KG. Moreover, the KG presented lower Bacillota/Bacteroidota ratio (p = 0.028), and BMI was positively associated with the Bacillota phylum. Conclusions: GTK did not enhance weight loss, but it decreased the LAP. GTK helped in the inflammatory profile and induced positive changes in oral microbiota composition.
Open AccessGreen Tea Kombucha Impacts Inflammation and Salivary Microbiota in Individuals with Excess Body Weight: A Randomized Controlled Trial
Background: Green tea kombucha (GTK) is a fermented beverage with promising health benefits, but few studies proved its impact on human health. Thus, we aimed to investigate the impact of GTK on weight loss, inflammation, and salivary microbiota in individuals with excess body weight. Methods: This is a randomized controlled clinical trial that lasted 10 weeks with two groups of individuals with excess body weight: control (CG; n = 29; caloric restriction) and kombucha (KG; n = 30; caloric restriction + 200 mL GTK). Body composition, anthropometry, saliva, and blood collection were performed in the beginning and end of the intervention. Plasma interleukins were determined by flow cytometry. Salivary microbiota was analyzed by 16S rRNA sequencing. Results: Both groups decreased weight, BMI, and body fat (p < 0.001) after the intervention, but there were no differences between groups. The KG reduced lipid accumulation product (LAP) (p = 0.029). Both groups decreased IL-1β and IL-8, but IL-6 increased in the CG (p = 0.023) compared to the kombucha group. Alpha and beta diversity of salivary microbiota increased in the KG. Moreover, the KG presented lower Bacillota/Bacteroidota ratio (p = 0.028), and BMI was positively associated with the Bacillota phylum. Conclusions: GTK did not enhance weight loss, but it decreased the LAP. GTK helped in the inflammatory profile and induced positive changes in oral microbiota composition.
- Open Access
- 26 July 2024
- Published by MDPI AG in Fermentation
- Vol. 10 (8) , 384
Black Tea Kombucha Consumption: Effect on Cardiometabolic Parameters and Diet Quality of Individuals with and without Obesity
Background: Kombucha, a fermented tea, has been suggested as an adjuvant in the treatment of obesity. Although animal and in vitro studies indicate its promising benefits, exploring kombucha’s impact on human health is necessary. Methods: This quasi-experimental pre–post-intervention assessed the effect of black tea kombucha consumption on cardiometabolic parameters for 8 weeks, considering the quality of the diet of individuals with and without obesity. Diet quality was assessed through the Dietary Inflammatory Index® and Dietary Total Antioxidant Capacity. Paired t-test/Wilcoxon was applied to compare differences between pre- and post-intervention (α = 0.05). Results: After the intervention, individuals with obesity showed a decrease in insulin, HOMA-IR, and GGT; those without obesity showed an increase in total cholesterol and alkaline phosphatase, but this was only observed in those with a worsened diet quality. Conclusion: kombucha intake demonstrated positive impacts on the metabolic health of individuals with obesity beyond the importance of combining it with healthy eating patterns.
- 26 July 2024
- Published by MDPI AG in Fermentation
- Vol. 10 (8) , 384
Open AccessBlack Tea Kombucha Consumption: Effect on Cardiometabolic Parameters and Diet Quality of Individuals with and without Obesity
Background: Kombucha, a fermented tea, has been suggested as an adjuvant in the treatment of obesity. Although animal and in vitro studies indicate its promising benefits, exploring kombucha’s impact on human health is necessary. Methods: This quasi-experimental pre–post-intervention assessed the effect of black tea kombucha consumption on cardiometabolic parameters for 8 weeks, considering the quality of the diet of individuals with and without obesity. Diet quality was assessed through the Dietary Inflammatory Index® and Dietary Total Antioxidant Capacity. Paired t-test/Wilcoxon was applied to compare differences between pre- and post-intervention (α = 0.05). Results: After the intervention, individuals with obesity showed a decrease in insulin, HOMA-IR, and GGT; those without obesity showed an increase in total cholesterol and alkaline phosphatase, but this was only observed in those with a worsened diet quality. Conclusion: kombucha intake demonstrated positive impacts on the metabolic health of individuals with obesity beyond the importance of combining it with healthy eating patterns.
- 26 October 2021
- Published by Taylor & Francis in Critical Reviews in Food Science and Nutrition
- Vol. 63 (19) , 3851-3866
Effect of kombucha intake on the gut microbiota and obesity-related comorbidities: A systematic review
Kombucha is a fermented nonalcoholic tea-based beverage produced through a symbiotic culture of bacteria and yeasts. In vitro studies have demonstrated antimicrobial, antioxidant, antiproliferative, and anti-carcinogenic properties of kombucha. However, no systematic reviews have evaluated the effects of kombucha in vivo. Thus, we aimed to evaluate the evidence that exists so far about kombucha consumption on comorbidities associated with obesity as well as on the gut microbiota. The search was conducted in accordance with PRISMA and the protocol was registered in PROSPERO (registration number: CRD42020158917). The MEDLINE/PubMed, Web of Science, LILACS, SciELO, Scopus, and Science Direct databases were used in the search considering the following terms: “kombucha” OR “kombucha tea” OR “kombucha teas” OR “tea, kombucha” OR “teas, kombucha” NOT “review.” Fifteen studies were included in this review. The results suggest that kombucha consumption attenuates oxidative stress and inflammation, improves the liver detoxification process, and reduces intestinal dysbiosis. There is evidence that kombucha consumption is beneficial for the control and treatment of obesity and associated comorbidities, as well as for the modulation of the gut microbiota in vivo.
- 26 October 2021
- Published by Taylor & Francis in Critical Reviews in Food Science and Nutrition
- Vol. 63 (19) , 3851-3866
Effect of kombucha intake on the gut microbiota and obesity-related comorbidities: A systematic review
Kombucha is a fermented nonalcoholic tea-based beverage produced through a symbiotic culture of bacteria and yeasts. In vitro studies have demonstrated antimicrobial, antioxidant, antiproliferative, and anti-carcinogenic properties of kombucha. However, no systematic reviews have evaluated the effects of kombucha in vivo. Thus, we aimed to evaluate the evidence that exists so far about kombucha consumption on comorbidities associated with obesity as well as on the gut microbiota. The search was conducted in accordance with PRISMA and the protocol was registered in PROSPERO (registration number: CRD42020158917). The MEDLINE/PubMed, Web of Science, LILACS, SciELO, Scopus, and Science Direct databases were used in the search considering the following terms: “kombucha” OR “kombucha tea” OR “kombucha teas” OR “tea, kombucha” OR “teas, kombucha” NOT “review.” Fifteen studies were included in this review. The results suggest that kombucha consumption attenuates oxidative stress and inflammation, improves the liver detoxification process, and reduces intestinal dysbiosis. There is evidence that kombucha consumption is beneficial for the control and treatment of obesity and associated comorbidities, as well as for the modulation of the gut microbiota in vivo.
- 12 July 2021
- Published by Springer Nature in European Journal of Nutrition
- Vol. 60 (6) , 2961-2977
Can resveratrol modulate sirtuins in obesity and related diseases? A systematic review of randomized controlled trials
Purpose Human sirtuins can be a powerful therapeutic target in preventing and treating obesity and age-related diseases. Some dietary components can modulate sirtuins’ activity, such as resveratrol. This systematic review aimed to assess whether resveratrol (RSV), without other interventions, can stimulate sirtuins in the treatment of excess weight and its comorbidities. Methods MEDLINE/Pubmed, EMBASE and Cochrane Central Register of Controlled Trials (CENTRAL) were used for search eligible articles. Randomized clinical trials assessing RSV supplementation on changes in the sirtuins’ gene expression/protein levels was the primary outcome. Other possible changes in cardiometabolic markers were considered the second outcome. Following PRISMA guidelines and using predefined inclusion and exclusion criteria, two reviewers independently and in parallel screened, assessed the studies' quality, and compiled data. Disagreements were resolved by consensus or consulting a third author. Results This review included seven randomized control trials. Four articles demonstrated a significant increase in SIRT-1 with different RSV dosages and interventions time. The secondary outcomes showed improvements in insulin sensitivity, lipid profile, metabolic flexibility, total antioxidant capacity, energy expenditure changes, and reduction of ectopic accumulation of fat. Conclusion Data from RCTs studies showed that RSV supplementation could stimulate SIRT-1 in humans, and therefore contribute to the treatment of excess weight and its comorbidities. However, more research is needed because it was not possible to confirm this effect truly. [PROSPERO registration number: CRD42020205571]
- 12 July 2021
- Published by Springer Nature in European Journal of Nutrition
- Vol. 60 (6) , 2961-2977
Can resveratrol modulate sirtuins in obesity and related diseases? A systematic review of randomized controlled trials
Purpose Human sirtuins can be a powerful therapeutic target in preventing and treating obesity and age-related diseases. Some dietary components can modulate sirtuins’ activity, such as resveratrol. This systematic review aimed to assess whether resveratrol (RSV), without other interventions, can stimulate sirtuins in the treatment of excess weight and its comorbidities. Methods MEDLINE/Pubmed, EMBASE and Cochrane Central Register of Controlled Trials (CENTRAL) were used for search eligible articles. Randomized clinical trials assessing RSV supplementation on changes in the sirtuins’ gene expression/protein levels was the primary outcome. Other possible changes in cardiometabolic markers were considered the second outcome. Following PRISMA guidelines and using predefined inclusion and exclusion criteria, two reviewers independently and in parallel screened, assessed the studies' quality, and compiled data. Disagreements were resolved by consensus or consulting a third author. Results This review included seven randomized control trials. Four articles demonstrated a significant increase in SIRT-1 with different RSV dosages and interventions time. The secondary outcomes showed improvements in insulin sensitivity, lipid profile, metabolic flexibility, total antioxidant capacity, energy expenditure changes, and reduction of ectopic accumulation of fat. Conclusion Data from RCTs studies showed that RSV supplementation could stimulate SIRT-1 in humans, and therefore contribute to the treatment of excess weight and its comorbidities. However, more research is needed because it was not possible to confirm this effect truly. [PROSPERO registration number: CRD42020205571]